Llwytho...
Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
BACKGROUND: Dupilumab blocks the shared receptor component for interleukin (IL)‐4/IL‐13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT02414854), add‐on dupilumab 200/300 mg every 2 weeks (q2w) reduced severe exacerbations, improved prebronchodila...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Allergy |
|---|---|
| Prif Awduron: | , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
John Wiley and Sons Inc.
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7820970/ https://ncbi.nlm.nih.gov/pubmed/33010038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/all.14611 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|